The poor antibody penetration across BBB, ADA neutralization of administrated antibodies, brain inflammation triggered by antigen–antibody complex deposition as well as adverse effects induced by impairment of phagocytosis capacities of microglia and astrocytes in AD brains can be challenges for AD passive immunotherapy studies. Here, ADA is linked to Alzheimer disease.